RAPT Therapeutics (RAPT) Operating Leases (2022 - 2024)
Historic Operating Leases for Therapeutics (RAPT) over the last 3 years, with Q3 2024 value amounting to $2.6 million.
- Therapeutics' Operating Leases fell 4879.73% to $2.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.6 million, marking a year-over-year decrease of 4879.73%. This contributed to the annual value of $4.5 million for FY2023, which is 3462.38% down from last year.
- As of Q3 2024, Therapeutics' Operating Leases stood at $2.6 million, which was down 4879.73% from $3.2 million recorded in Q2 2024.
- Over the past 5 years, Therapeutics' Operating Leases peaked at $7.1 million during Q1 2022, and registered a low of $2.6 million during Q3 2024.
- In the last 3 years, Therapeutics' Operating Leases had a median value of $5.7 million in 2023 and averaged $5.3 million.
- Per our database at Business Quant, Therapeutics' Operating Leases tumbled by 1214.85% in 2023 and then crashed by 4879.73% in 2024.
- Quarter analysis of 3 years shows Therapeutics' Operating Leases stood at $6.8 million in 2022, then crashed by 34.62% to $4.5 million in 2023, then plummeted by 41.75% to $2.6 million in 2024.
- Its Operating Leases was $2.6 million in Q3 2024, compared to $3.2 million in Q2 2024 and $3.8 million in Q1 2024.